Pyrazinamide
| DRUG INFORMATION |
| Drug Name |
| Pyrazinamide |
 |
| Synonyms |
| Pirazinamida, 2-Carbamyl pyrazine, 2-Pyrazinecarboxamide, Pyrazine-2-carboxamide, Pyrazine carboxylamide, pyrazineamide, Pyrazinecarboxamide, Pyrazinoic acid amide, pyrazinamide, Aldinamide, Aldinamid, Unipyranamide, Pirazinamid, Pirazimida, Farmizina, Tebrazid, Zinamide |
| Drug Class |
| First-Line Drugs |
| Year of Introduction |
| 1970 |
| Molecular Target |
| ? Rv2043c |
| Genes Involved in Drug Resistance |
| pncA |
| CAS No: |
| 98-96-4 |
| PHARMACOLOGY |
| Route |
| oral |
| Side effects |
| Frequent: non-gouty polyarthralgia (up to 40%, rx with ASA); asymptomatic hyperuricemia. Occ: hepatitis (dose related--1% at 25mg/kg), monitor LFTs closely with RIF x 2mos); GI intolerance. Rare: gout (rx w/ allopurinol and probenecid). |
| Toxicity |
| Low |
| Cost |
| Medium |
| Usual Adult Dosage |
| 20-25mg/kg (max 2gm) PO qd. DOT regimen: 50-70mg/kg (max 3.5gm) PO 2x/week or 50-70mg/kg (max 2.5gm) PO 3x/week. |
| Form |
| tab, cap |
| Brand Name |
| Pyrazinamide , Rifater |
| Manufacturer |
| various(Rifater by Aventis) |
| STRUCTURAL DETAILS |
| Molecular Formula |
| C5H5N3O |
| Molecular Weight in g/mol |
| 123.113 |
| Hydrogen Bond Donor Count |
| 1 |
| Hydrogen Bond Acceptor Count |
| 3 |
| Rotatable Bond Count |
| 1 |
| IUPAC Name |
| pyrazine-2-carboxamide |
| SMILES |
| C1=CN=C(C=N1)C(=O)N |
| InChI |
| 1/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)/f/h6H2 |
New Search